Abstract: See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/346639384 Outcome of ivermectin and doxycycline in cancer patients with COVID-19: A positive experience in Bangladesh Article in International Journal of Molecular and Immuno Oncology · December 2020 DOI: 10.25259/IJMIO_30_2020 CITATIONS READS 2 1,787 3 authors, including: s.M Hussain Md Shuayb Square Hospitals Limited Vancouver General Hospital 2 PUBLICATIONS 6 CITATIONS 20 PUBLICATIONS 20 CITATIONS SEE PROFILE Some of the authors of this publication are also working on these related projects: Chemotherapy View project Head and Neck Cancer View project All content following this page was uploaded by Md Shuayb on 04 December 2020. The user has requested enhancement of the SEE PROFILE www.ijmio.com International Journal of Molecular & Immuno Oncology Article in Press Short Communication Outcome of ivermectin and doxycycline in cancer patients with COVID-19: A positive experience in Bangladesh Syed Md Akram Hussain1, Md Shuayb2, Mahmudur Rahman3 Department of Oncology, Square Hospitals, West Panthapath, Dhaka, Bangladesh, 2Vancouver Prostate Centre, Vancouver General Hospital, The University of British Columbia, Vancouver, Canada, 3Emerging Infections Program, IDD, International Centre for Diarrhoeal Disease Research, Mohakhali, Dhaka, Bangladesh. 1 *Corresponding author: Syed Md Akram Hussain, Department of Oncology, Square Hospitals, West Panthapath, Dhaka, Bangladesh. syedmdakram@gmail.com Received : 17 September 2020 Accepted : 20 October 2020 Published : DOI: 10.25259/IJMIO_30_2020 Quick Response Code: The world, today, is facing an immense challenge with the outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection known as coronavirus disease 2019 (COVID-19). Bangladesh is the 16th ranked pandemic part of the world with 244,020 cases diagnosed and 3234 deaths to date.[1] At present, no FDA approved remedies are available to defeat this deadly disease. Ivermectin, an antiparasitic drug, has been found to inhibit the replication of the SARS-CoV-2 virus in vitro.[2] When combined with doxycycline, an antibacterial drug, ivermectin showed encouraging activity in reducing viral load, possible molecular mechanisms of which have been proposed very recently.[3,4] Globally, a number of clinical trials are going on to explore the activity of these two widely used FDA approved drugs as a potential therapy for SARS-CoV-2 infection. Although no systematic data are available, several studies including the European Society for Medical Oncology and the National Institute for Health and Care Excellence guidelines have reported that cancer patients are more vulnerable to develop COVID-19 infection.[5] We sought to investigate the effectiveness of ivermectin plus doxycycline in COVID-19-positive cancer patients in a tertiary care cancer center of Dhaka city in Bangladesh. This is a case series conducted at the Oncology and Radiotherapy Centre of Square Hospital, Bangladesh. A total of eight patients were treated with ivermectin and doxycycline combination to date, who met the eligibility criteria. The primary outcome was treatment response and the secondary outcome was treatment-related toxicity. Inclusion criteria included in this study were patients with any stage of solid malignancies or lymphoma proved by pathology; active disease being treated with chemotherapy and/or..